Navigation Links
Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients
Date:5/31/2009

was preceded by a deviation in baseline ImmuKnow status. Immunosuppression was adjusted in each case, accordingly, without evidence of graft loss or clinical symptoms." He concluded by saying, "Viral surveillance together with ImmuKnow can be useful to prevent infection or organ rejection by tailoring immunosuppressive therapy." For each patient, viral studies and ImmuKnow results were routinely obtained and immunosuppressive drug dosing was adjusted based on positive viral studies using ImmuKnow results as an adjunct tool.

In a related study, researchers at the University of North Carolina at Chapel Hill and Ohio State University prospectively studied the use of the ImmuKnow assay together with various viral markers in 93 renal transplant recipients. Lead study investigator, Dr. Kenneth A. Andreoni, summarized the results of the study by saying, "We collected ImmuKnow data along with viral monitoring. From our data, we feel we may be able to prevent some viral infections by decreasing immunosuppression when ImmuKnow assay values are <100ng/ml or when post-transplant baseline ImmuKnow values decrease by >50%." Among patients who developed elevated viral levels, the majority either displayed an ImmuKnow value <100ng/ml or >50% decrease in baseline ATP value. In several of these patients, low ImmuKnow results led directly to immunosuppression medication decreases and subsequent increases in ImmuKnow with no infections or rejections.

The use of the ImmuKnow assay as described in these studies has not been cleared by the U.S. Food & Drug Administration.

About ImmuKnow

ImmuKnow is a noninvasive biomarker of immune function that assesses cellular immune status by detecting cell-mediated immunity (CMI) in adult immunosuppressed patients. It measures the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation. T
'/>"/>

SOURCE Cylex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
2. Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
3. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
4. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
5. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
8. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
9. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
10. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
11. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Bio-Techne Corporation (NASDAQ: TECH ) announced today ... the new Simple Plex platform through its Proteins Platform ... re-branding of the previously acquired CyPlex instrument platform from ... transformative immunoassay technology which integrates an innovatively designed microfluidic ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
(Date:1/22/2015)... The Parenteral Drug Association (PDA) today announced the launch ... Pharmaceutical Manufacturing,s Future. The Manufacturing Science ... , Highlight the ongoing focus PDA has on pharmaceutical and ... filling known gaps in current manufacturing science as well as ...
Breaking Medicine Technology:Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3PDA Launches Manufacturing Science Program(SM) 2PDA Launches Manufacturing Science Program(SM) 3
... MedImmune today announced,that it has initiated a Phase ... healthy children one month to 12 months of age ... is,the most common respiratory infection in infants and can ... is a serious respiratory disease that can have significant ...
... Meeting -, - Conference call to be hosted ... BRANFORD, Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRGN ... II,trial of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, ... Stage IV melanoma.,Dr. Patrick Hwu, Co-Principal Investigator, and Professor ...
Cached Medicine Technology:MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7
(Date:1/22/2015)... Hawley, PA (PRWEB) January 22, 2015 Woodloch ... Pocono Mountains, has been selected by TripAdvisor as the number ... and the 6th best in the world for their annual ... online travel community . The website is home to ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 The Incredible Bulk ... Ben Pakulski to increase lean muscle by up to 30lbs ... caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative ... it is a step-by-step, scientific diet formula that allows the ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... released a new blog post explaining the main features of ... Auto insurance quotes help many drivers find the best coverage ... an agent or visit an agency for price information. These ... http://autocarinsurancebest.com/ . , Every business who relies heavily on transportation ...
(Date:1/22/2015)... 22, 2015 A study recently ... flagship journal Medicine & Science in Sports & ... may help reduce gastrointestinal (GI) problems associated with ... Participants in the double-blind, placebo-controlled study took 10 ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Nigam, a top-notch Hindi singer, says that men are ... s managed to catch the attentions of many people. Sonu ... harassing him for sexual favors in return for publicity. ... now was employed against the girls in the industry. ...
... talked up the virtues of dog meat, saying the controversial ... heat . ,Dog soup, called dangogi-jang or boshintang ... season, the official Korean Central News Agency said, touting its ... an euphemism for dog meat that was coined by North ...
... UN experts, food safety is an issue for every country ... the almost 200 food safety incidents that occurred in the ... all countries to be vigilant when dealing with traders and ... examples, the Food and Agriculture Organization (FAO) and the World ...
... the University Clinic of the University of Navarra have ... adult stem cell growth for its capacity to ... ,Ana Fernandez Hortelano, ophthalmologist at the hospital, applied ... cornea in 70 rabbits for the purpose of regaining ...
... finasteride, a drug proven effective in preventing prostate cancer, just ... bedroom, can now put their fears to rest, thanks to ... the Southwest Oncology Group, found that though the drug does ... the course of time. ,As a part of ...
... antidepressants, and if so, should they be given ... by the National Institute for Health and Clinical ... bmj.com last month found that adding cognitive behaviour ... treatment is unlikely to improve outcomes for adolescents ...
Cached Medicine News:Health News:Male Casting Couch in Bollywood? 2Health News:Male Casting Couch in Bollywood? 3Health News:Gaps In Food Safety Systems Must Be Plugged :UN 2Health News:Mens Sexual Prowess Not Affected by Prostate Cancer Drug 2Health News:New Study Challenges NICE Guidelines on Adolescent Depression 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: